These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27762625)

  • 1. Implantable cardioverter defibrillator management: an update.
    Malagù M; Ferri A; Mancuso O; Trevisan F; Nardozza M; Bertini M
    Future Cardiol; 2016 Nov; 12(6):673-688. PubMed ID: 27762625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing.
    Poole JE; Gold MR
    Circ Arrhythm Electrophysiol; 2013 Dec; 6(6):1236-44; discussion 1244-5. PubMed ID: 24347599
    [No Abstract]   [Full Text] [Related]  

  • 3. The implantable cardioverter-defibrillator: An update.
    Miller JD; Yousuf O; Berger RD
    Trends Cardiovasc Med; 2015 Oct; 25(7):606-11. PubMed ID: 25912255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous implantable cardioverter defibrillator: Can it overtake its transvenous counterpart.
    Savarimuthu S; Roy S; Obeidat M; Harky A
    Pacing Clin Electrophysiol; 2021 Aug; 44(8):1413-1420. PubMed ID: 33878197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of sudden cardiac death: from wearable to subcutaneous cardioverter defibrillator.
    Viani S; Soldati E; DI Cori A; Segreti L; Paperini L; DE Lucia R; Zucchelli G; Bongiorni MG
    Minerva Cardioangiol; 2018 Feb; 66(1):83-99. PubMed ID: 28696089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The totally subcutaneous implantable defibrillator.
    Rhyner J; Knight BP
    Cardiol Clin; 2014 May; 32(2):225-37. PubMed ID: 24793799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of remote monitoring on patient-reported outcomes in European heart failure patients with an implantable cardioverter-defibrillator: primary results of the REMOTE-CIED randomized trial.
    Versteeg H; Timmermans I; Widdershoven J; Kimman GJ; Prevot S; Rauwolf T; Scholten MF; Zitron E; Mabo P; Denollet J; Pedersen SS; Meine M
    Europace; 2019 Sep; 21(9):1360-1368. PubMed ID: 31168604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sudden cardiac death in the youth. Is the new subcutaneous implantable cardioverter defibrillator S-ICD an alternative solution?].
    Roche NC; Stefuriac M; Dumitrescu N; Charbonnel A; Godreuil C; Bonnevie L
    Ann Cardiol Angeiol (Paris); 2015 Feb; 64(1):27-31. PubMed ID: 25281995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The subcutaneous cardioverter-defibrillator: When less is more].
    Kuschyk J; Rudic B; Akin I; Borggrefe M; Röger S
    Herzschrittmacherther Elektrophysiol; 2015 Jun; 26(2):123-8. PubMed ID: 26058997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?
    Randles DA; Hawkins NM; Shaw M; Patwala AY; Pettit SJ; Wright DJ
    Europace; 2014 Jul; 16(7):1015-21. PubMed ID: 24351884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction.
    Chan LL; Lim CP; Aung ST; Quetua P; Ho KL; Chong D; Teo WS; Sim D; Ching CK
    Singapore Med J; 2016 Apr; 57(4):182-7. PubMed ID: 27075476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Important Parameters for Implantable Cardioverter Defibrillator Selection.
    Zungsontiporn N; Loguidice M; Daniels J
    Card Electrophysiol Clin; 2018 Mar; 10(1):145-152. PubMed ID: 29428136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal trends and long term follow-up of implantable cardioverter defibrillator therapy for secondary prevention: A 15-year single-centre experience.
    Caputo ML; Regoli F; Conte G; Adjibodou B; Svab S; Del Bufalo A; Moccetti T; Curti M; Klersy C; Auricchio A
    Int J Cardiol; 2017 Feb; 228():31-36. PubMed ID: 27863358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillator implantation for primary and secondary prevention: indications and outcomes.
    Pick JM; Batra AS
    Cardiol Young; 2017 Jan; 27(S1):S126-S131. PubMed ID: 28084973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.